Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexidartinib discontinuation and re-treatment study in previously treated TGCT
NL-OMON52692Phase 4Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pexidartinib in tenosynovial giant cell tumor (TGCT) (2 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Proportion of subjects who remain treatment-free at Month 12 and Proportion of subjects who remain treatment-free at Month 24. Started Jan 2021; status: active, not recruiting.
02
Drugs
pexidartinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NL-OMON52692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52692.